Xenomics begins enrollment in trial for Transrenal DNA tuberculosis test

By E. Janene Geiss

Philadelphia, June 14 - Xenomics, Inc. said Wednesday that it began patient enrollment in Europe for its clinical development program of a tuberculosis test using its proprietary Transrenal DNA-based technology.

SpaXen Italia, a collaborative venture between Xenomics and Italy's National Institute for Infectious Diseases "Lazzaro Spallanzani," will lead an international consortium focusing on the development of a diagnostic test for tuberculosis using Xenomics' Transrenal-DNA technology, according to a company news release.

Currently, the definitive diagnostic test for tuberculosis is a culture, which takes up to three months to complete and is not always reliable, officials said.

Therefore, individuals with tuberculosis often may be unaware of their condition during that period, during which they may be highly infectious. This is a serious problem in many parts of the developing world and a growing problem in the United States, officials said.

"Xenomics' technology is based upon the fact that cellular DNA from throughout the body cross the kidney barrier and accumulates in the urine," L. David Tomei, chief executive officer and co-founder of Xenomics, said in the release.

The company said using an analysis of urine samples, these Transrenal-DNA fragments provide immediate and vital information about a wide range of conditions inside the body, including serious infectious diseases.

Xenomics is a New York molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.